Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Immunotherapy research partnership agreement

Immunocore : 09 January, 2014  (Company News)
Immunocore and MedImmune have reached an agreement to collaborate on the research of immunotherapy for the treatment of cancer
Immunotherapy research partnership agreement


Immunocore, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.



The platform of biological medicines, or ImmTACs, exploit the power of the body’s own immune system to find and kill diseased cells. ImmTACs direct a patient’s T cells to target and destroy only the cancerous cells, leaving healthy tissue undamaged.



Immunocore and MedImmune will work together to generate ImmTACs against selected cancer targets. AstraZeneca and MedImmune will have the right to further develop and commercialise ImmTAC products to add to their immune-mediated cancer therapy portfolio. Immunocore will receive an upfront payment of $20 million per programme and the company is eligible to receive up to $300 million in development and commercial milestone payments for each target programme and significant tiered royalties.



This deal marks the third major partnership agreement for Immunocore in the last six months, following major research and licensing agreements with Genetech and GlaxoSmithKline in summer 2013.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo